Shares of Editas Medicine EDIT gained 4.2% on Monday after the company announced updated safety and efficacy data from the severe sickle cell disease (SCD) study of its lead candidate, renizgamglogene ...

Although it's a clinical-stage company, the biotech handily beat the consensus analyst estimate for second-quarter revenue. It whiffed mightily on earnings, but investors obviously didn't mind. Editas ...

Editas Medicine (NASDAQ:EDIT – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday. Several other equities ...

Editas Medicine Inc. (NASDAQ:EDIT) announced last week a strategic realignment to focus on in vivo gene editing. The shift is designed to optimize costs, extend its cash runway into the second quarter ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

Shares of Editas Medicine Inc. (EDIT) fell more than 6% in after-hours trading on Wednesday after posting a ...

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of ...

Editas published the earnings release on Tuesday. The clinical-stage biotech earned slightly under $3.6 million in revenue during the period, which was entirely derived from collaboration and other ...